Aspirin has analgesic, anti-inflammatory and antipyretic actions. It inhibits platelet aggregation by inactivation of platelet cyclo-oxygenase, the enzyme that produces the cyclic endoperoxide precursor of thromboxane A2.
Indications related to inhibition of platelet aggregation: To reduce the risk of myocardial infarction in patients with unstable angina or in patients who have had a previous myocardial infarction. To reduce the risk of recurrent transient ischaemic attacks or stroke in men who have had transient ischaemia of the brain due to fibrin platelet emboli. To reduce the risk of graft occlusion following aorta coronary by-pass surgery.
Patients with a history of gastro-intestinal bleeding or perforation (PUBs) related to previous NSAIDs. Patients with active or a history of recurrent ulcer/haemorrhage/perforations. Patients with haemophilia. Intolerance (hypersensitivity) to aspirin. Severe renal or hepatic impairment. Heart failure. Patients receiving oral anti-coagulant therapy.
